Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK10 | P53779 | 9/20 | 0.41 |
| ▸ | MAPK8 | P45983 | 5/20 | 0.40 |
| ▸ | GSK3A | P49840 | 3/20 | 0.39 |
| ▸ | GSK3B | P49841 | 3/20 | 0.39 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.36 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 1/20 | 0.34 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.34 |
| ▸ | SRPK1 | Q96SB4 | 4/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29742368 | 1.00 | MAPK10 (0.41) | MAPK10MAPK8GSK3AGSK3BADRA1D | |
| SCHEMBL20209389 | 0.93 | MAPK10 (0.40) | MAPK10MAPK8GSK3AGSK3BADRA1D | |
| SCHEMBL20189517 | 0.93 | MAPK10 (0.40) | MAPK10MAPK8GSK3AGSK3BADRA1D | |
| SCHEMBL29742254 | 0.93 | MAPK10 (0.40) | MAPK10MAPK8GSK3AGSK3BADRA1D | |
| SCHEMBL20189514 | 0.85 | ADRA1D (0.42) | MAPK10MAPK8GSK3AGSK3BADRA1D | |
| SCHEMBL29742268 | 0.85 | ADRA1D (0.42) | MAPK10MAPK8GSK3AGSK3BADRA1D | |
| SCHEMBL20209251 | 0.84 | MAPK10 (0.40) | MAPK10MAPK8GSK3AGSK3BADRA1D | |
| SCHEMBL20189887 | 0.84 | MAPK10 (0.40) | MAPK10MAPK8GSK3AGSK3BADRA1D | |
| SCHEMBL29742325 | 0.84 | MAPK10 (0.40) | MAPK10MAPK8GSK3AGSK3BADRA1D | |
| SCHEMBL20190708 | 0.83 | GSK3A (0.42) | MAPK10MAPK8GSK3AGSK3BADRA1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110198934-B | Pyrimidine carboxamides as GSK-3 inhibitors | 百时美施贵宝公司 | 2022-07-22 | — | — | CN | disclosed |
| US-11053258-B2 | Pyrimidine carboxamides as GSK-3 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-07-06 | — | — | US | disclosed |
| US-11053258-B2 | Pyrimidine carboxamides as GSK-3 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-07-06 | — | — | US | disclosed |
| EP-3544968-B1 | PYRIMIDINE CARBOXAMIDES AS GSK-3 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2020-12-30 | — | — | EP | disclosed |
| EP-3544968-B1 | PYRIMIDINE CARBOXAMIDES AS GSK-3 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2020-12-30 | — | — | EP | disclosed |
| US-20200181170-A1 | PYRIMIDINE CARBOXAMIDES AS GSK-3 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2020-06-11 | — | — | US | disclosed |
| US-20200181170-A1 | PYRIMIDINE CARBOXAMIDES AS GSK-3 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2020-06-11 | — | — | US | disclosed |
| EP-3544968-A1 | PYRIMIDINE CARBOXAMIDES AS GSK-3 INHIBITORS | Bristol-Myers Squibb Company (US) | 2019-10-02 | — | — | EP | disclosed |
| WO-2018098413-A1 | PYRIMIDINE CARBOXAMIDES AS GSK-3 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-05-31 | — | — | WO | disclosed |
| WO-2018098413-A1 | PYRIMIDINE CARBOXAMIDES AS GSK-3 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11053258-B2 | Pyrimidine carboxamides as GSK-3 inhibitors | GSK3B, GSK3A, GSKIP | MAPK10 943/4885MAPK8 934/4885GSK3A 2/4885 |
| US-20200181170-A1 | PYRIMIDINE CARBOXAMIDES AS GSK-3 INHIBITORS | GSK3B, GSK3A, GSKIP | MAPK10 943/4885MAPK8 934/4885GSK3A 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.